BRIEF published on 11/05/2025 at 18:01, 10 months 11 days ago Christian Mias Appointed as New CEO of SCHOTT Pharma CEO Appointment SCHOTT Pharma Leadership Change Christian Mias Andreas Reisse
PRESS RELEASE published on 11/05/2025 at 17:56, 10 months 11 days ago EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: Christian Mias to succeed Andreas Reisse as CEO SCHOTT Pharma AG & Co. KGaA appoints Christian Mias as CEO to succeed Andreas Reisse, effective May 1, 2026. Inside information disclosed. Press release via EQS News Inside Information CEO Appointment SCHOTT Pharma EQS News Christian Mias
BRIEF published on 08/12/2025 at 07:05, 1 year 1 month ago SCHOTT Pharma Reports Steady Q3 2025 Results Innovation SCHOTT Pharma High-value Solutions Drug Containment Q3 2025 Results
PRESS RELEASE published on 08/12/2025 at 07:00, 1 year 1 month ago SCHOTT Pharma delivers solid final third-quarter results SCHOTT Pharma reports solid Q3 2025 results with 1% revenue growth, 32.4% EBITDA margin, and strategic innovations Revenue Growth EBITDA Margin SCHOTT Pharma Innovations Q3 2025 Results
BRIEF published on 08/05/2025 at 10:00, 1 year 1 month ago SCHOTT Pharma's Q3 2025 Highlights and FY 2025 Outlook Revenue Growth EBITDA Margin Financial Outlook Q3 2025 High Value Solutions
BRIEF published on 08/05/2025 at 09:58, 1 year 1 month ago SCHOTT Pharma Updates FY 2025 Revenue and EBITDA Guidance Financial Results Revenue Growth EBITDA Margin SCHOTT Pharma FY 2025 Guidance
PRESS RELEASE published on 08/05/2025 at 09:55, 1 year 1 month ago SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance SCHOTT Pharma reports Q3 2025 revenues up 3% yoy at EUR 256m and gives FY 2025 guidance with EBITDA expected to be around 28.0%. Full financial results to be published on August 12, 2025 Revenues EBITDA SCHOTT Pharma Q3 2025 FY 2025 Guidance
PRESS RELEASE published on 08/05/2025 at 09:53, 1 year 1 month ago EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin SCHOTT Pharma AG & Co. KGaA specifies FY 2025 guidance for revenue growth and EBITDA margin, expecting 6.0% organic revenue growth and 28.0% EBITDA margin Revenue Growth EBITDA Margin SCHOTT Pharma Guidance FY 2025
BRIEF published on 06/11/2025 at 08:55, 1 year 3 months ago SCHOTT Pharma Extends CEO Contract and Appoints New CFO Global Expansion CEO Contract Extension Innovative Leadership New CFO Appointment Pharmaceutical Containment
PRESS RELEASE published on 06/11/2025 at 08:50, 1 year 3 months ago SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO SCHOTT Pharma extends CEO's contract Andreas Reisse & appoints Reinhard Mayer as CFO. Strategic personnel changes at SCHOTT Pharma AG & Co. KGaA CFO Appointment SCHOTT Pharma Personnel Changes CEO Contract Reinhard Mayer
Published on 09/16/2026 at 23:45, 5 hours 22 minutes ago Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 7 hours 37 minutes ago Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 12 hours 12 minutes ago CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 14 hours 7 minutes ago 2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 15 hours 7 minutes ago Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update
Published on 09/17/2026 at 04:25, 41 minutes ago Zhou Jianjun from Huawei: Building a Grid-Interactive AIDC Solution to Maximize Tokens Per Watt
Published on 09/16/2026 at 23:45, 5 hours 21 minutes ago WESCAN GOLDFIELDS COMMENCES UAV MAGNETIC AND LIDAR SURVEYS AT MUNRO LAKE PROJECT
Published on 09/16/2026 at 22:33, 6 hours 33 minutes ago EQS-Adhoc: Bilfinger adjusts outlook for 2026 and resolves program “Agile”
Published on 09/16/2026 at 21:15, 7 hours 51 minutes ago Gastech 2026 in Bangkok Converts Global Energy Ambition into Billions of Dollars in Deals
Published on 09/16/2026 at 20:27, 8 hours 39 minutes ago EQS-Adhoc: REPLOID Group AG resolves to issue convertible notes in an aggregate principal amount of up to EUR 30 million
Published on 09/16/2026 at 17:45, 11 hours 22 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 22 hours 7 minutes ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 11 hours ago Report on the Combined General Meeting of the 10th of September 2026
